Anand Popuri, DO
Pulmonary Disease · Hermitage, TNNPI 1861754319
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (53.2%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 49 manufacturers reported payments, led by GSK at 41.3% of the total. 2025 is the largest year on record at $6,149, 3.3 times the $1,847 reported in 2019.
Across 520 payments — averaging $42.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$9K
- Johnson & Johnson$3K
- AstraZeneca$1K
- Boehringer Ingelheim$1K
- Medical Device Business Services, Inc.$1K
- Intuitive Surgical$1K
- plus $5K from 43 others
What the payments were for
- Speaking & faculty fees$7,50034%
- Travel & lodging$2,72912%
- Food & beverage$11,81653%
- Education$1481%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NUCALA$4,018
- TRELEGY ELLIPTA$3,600
- MONARCH$1,156
- Monarch Platform$715
- Da Vinci Surgical System$687
- GALAXY$463
How this compares
$22,193 in reported general payments places this provider in the 85th percentile of 339 pulmonary disease providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 310 | $283,973 |
| OfevNintedanib Esylate | 11 | $143,248 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 87 | $53,775 |
| Breo ElliptaFluticasone/Vilanterol | 76 | $37,136 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 25 | $14,342 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 15 | $14,171 |
| EliquisApixaban | 23 | $13,233 |
| XareltoRivaroxaban | 22 | $12,399 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 56 | $9,321 |
| Spiriva RespimatTiotropium Bromide | 16 | $8,163 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 202 | $7,808 |
| SymbicortBudesonide/Formoterol Fumarate | 21 | $6,546 |
| Wixela InhubFluticasone Propion/Salmeterol | 36 | $5,923 |
| Advair HfaFluticasone Propion/Salmeterol | 11 | $4,563 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 19 | $3,089 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $9,172 | $374,883473 claims |
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat | $1,398 | $165,75252 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,489 | $20,71736 claims |
| PfizerEliquis | $182 | $13,23323 claims |
| Johnson & JohnsonXarelto | $2,533 | $12,39922 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 339 pulmonary disease providers in Tennessee.
Other pulmonary disease in Hermitage
- Lisa LancasterNashville$519K
- Krishnendu BhadraChattanooga$494K
- Aaron MilstoneFranklin$482K
- Otis RickmanNashville$392K
- Michael CzarneckiChattanooga$348K
- Susan GarwoodNashville$343K
- Girendra HoskereBristol$285K
- Carlos BaleeiroChattanooga$265K
- Joao DeandradeNashville$245K
- John SwisherKnoxville$234K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.